Read our latest updates & insights

On 15 March 2024, CuraTeQ Biologics (a subsidiary of Aurobindo) announced that it successfully completed phase I trials for omalizumab biosimilar (BP11), demonstrating pharmacokinetic and pharmacodynamic equivalence to Genentech’s/Novartis’ US and EU-sourced Xolair®.  The t...

On 14 March 2024, Biocon Biologics announced that it has entered a long-term commercial collaboration with Eris Lifesciences, including to increase access to its biosimilars in India.  The deal, worth INR 12,420 million, involves a 10-year supply agreement with Eris and ove...

On 14 March 2024, AstraZeneca announced that it has entered into an agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.  Amoylt’s portfolio notably includes eneboparatide (AZP-3...

On 13 March 2024, Sandoz reported double-digit growth of 15% in its 2023 biosimilar sales.  Sandoz attributed this growth to the launch of Hyrimoz®(biosimilar to AbbVie’s Humira®,adalimumab)  in the US and entering an agreement to commercialise Samsung Bioepis’ SB17 (biosim...